A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer
A phase 1/2 trial of TAK-788 in non-small-cell lung cancer, run by Takeda, active and no longer recruiting.
Overview
A Study of TAK-788 in Adults With Non-Small Cell Lung Cancer is a phase 1/2 interventional study registered as NCT02716116 by Takeda, with 334 participants enrolled, started 2016-06-16 and due to reach its primary completion in 2026-10-31. Interventions recorded: TAK-788.
Setting
A Phase 1/2 Study of the Safety, Pharmacokinetics, and Anti-Tumor Activity of the Oral EGFR/HER2 Inhibitor TAK-788 (AP32788) in Non-Small Cell Lung Cancer
Phase
Phase 1/2
Sponsor
Takeda
Registry
Enrolled
334
Similar pages
not linked directly; found by shared links- TrialA Study of TAK-188 in Adults With Advanced or Spreading Solid Tumors
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-505 in Adults With Solid Tumors
Shares Takeda and the tag pipeline.
- TrialA Study of Gammagard Liquid (Immune Globulin Infusion, 10%) to Prevent Infections in Adults With Multiple Myeloma
Shares Takeda and the tag pipeline.
- TrialA Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
Shares Takeda and the tag pipeline.
- TrialAllogeneic PB103 (NK Cells) Therapy in Non-small Cell Lung Cancer (NSCLC) Patients
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialStudy to Evaluate Sutetinib Maleate Capsule in Locally Advanced or Metastatic Non-small Cell Lung Cancer
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialA Phase 1/2 Study to Evaluate the Safety, Tolerability and PK of JIN-A02 in Patients With EGFR Mutant Advanced NSCLC
Shares Non-small-cell lung cancer and the tag pipeline.
- TrialPhase 1/2 Study of HS-10375 in Patients with Advanced or Metastatic Non-Small-Cell Lung Cancer(NSCLC)
Shares Non-small-cell lung cancer and the tag pipeline.